| KKR & CO INC. |
| USA |
| Finanzen |
| US48251W1045 / A2LQV6 |
| KR51 (Frankfurt) / KKR (NYSE) |
| FRA:KR51, ETR:KR51, KR51:GR, NYSE:KKR |
| - |
| https://www.kkr.com/ |
|
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address dis..
>Volltext.. |
| 79362.63 Mio. EUR |
| 154165.71 Mio. EUR |
| 22250.63 Mio. EUR |
| 4163.86 Mio. EUR |
| 3096.71 Mio. EUR |
| 3.3 EUR |
| 49763.99 Mio. EUR |
| 20541.34 Mio. EUR |
| 7651.24 Mio. EUR |
| 1.36 |
| 43.47% |
| 50.44% |
| 0.49 EUR |
| 0.78% |
| 0.8% |
| 10.08.26 - 0.1688895€ 15.05.26 - 0.167661€ >weitere anzeigen... |
| - |
| KKR & CO, KOHLBERG KRAVIS, KKR |
| 17.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|